Clinical trials: Uremic Pruritus
Uremic Pruritus, Pruritus
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
The primary objectives of the study to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in hemodialysis patients with moderate to severe…
- Trial name
- NCT02143648
- Testing
- nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID
- Where
- 47 sites in United States, Poland and 1 more
- Volunteers
- 373 people
- Sponsor
- Trevi Therapeutics
Uremic Pruritus in Hemodialysis Patients
A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
The purpose of this study is to evaluate the efficacy, safety and dose response of SK-1405 for the treatment of subjects with uremic pruritus receiving hemodialysis, during 2 weeks of treatment.
- Trial name
- NCT03218501
- Testing
- SK-1405 high dose, SK-1405 low dose
- Where
- Japan
- Volunteers
- 269 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Uremic Pruritus
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
- Trial name
- NCT03281538
- Testing
- CR845
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- Cara Therapeutics, Inc.
Uremic Pruritus
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis
This is a multi-center, randomized, double-blind, placebo-controlled phase II clinical trial. The main objective is to evaluate the safety, pharmacokinetics, and efficacy of HSK21542 injection in subjects undergoing hemodialysis
- Trial name
- NCT04470154
- Testing
- Stage I:HSK21542 0.05 μg/kg, Stage I:HSK21542 0.15 μg/kg, Stage I:HSK21542 0.30 μg/kg
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Uremic Pruritus, Pruritus
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.
- Trial name
- NCT02143973
- Testing
- nalbuphine HCl ER
- Where
- 35 sites in United States
- Volunteers
- 167 people
- Sponsor
- Trevi Therapeutics
Uremic Pruritus
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Double-blind, Placebo-controlled study to confirm the superiority of MR13A9 to placebo, and followed by extension, open-label treatment to confirm long-term safety of MA13A9 in hemodialysis patients with pruritus.
- Trial name
- NCT04711603
- Testing
- MR13A9
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Uremic Pruritus
Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
This is a single-center clinical research study with the purpose to evaluate the safety, tolerability, and pharmacokinetics (PK) of nalbuphine HCl ER (extended release) tablets in end-stage renal disease (ESRD) patients receiving…
- Trial name
- NCT02373215
- Testing
- Nalbuphine HCL ER
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Trevi Therapeutics